"Staphylococcus aureus"@en . . . . . . . . "1 hour. In subjects with moderate impairment of renal function the plasma half-life was prolonged to approximately 5.6 hours."@en . "Various gram-negative and gram-positive eubacteria"@en . . "Loracarbef"@en . . "Loracarbef is an oral, synthetic beta-lactam antibiotic of the carbacephem class. Chemically, carbacephems differ from cephalosporin-class antibiotics in the dihydrothiazine ring where a methylene group has been substituted for a sulfur atom. Loracarbef has a spectrum of activity similar to that of the second generation cephalosporins. It is structurally identical to cefaclor except for a sulfur atom that has been replaced by a methylene group. This change gives greater chemical stability in solution and allows storage at room temperature. Loracarbef, like all b-lactams and cephalosporins, inhibits penicillin binding proteins, enzymes that create the cross-linkage of the peptidoglycan polymer. This binding leads to interference with the formation and remodeling of the cell wall structure."@en . . "Well absorbed with approximately 90% absorbed from the gastrointestinal tract after oral ingestion."@en . . . . . . "Haemophilus influenzae"@en . . "William C. Henning, Theodore R. Stout, \"Process for preparing loracarbef monohydrate.\" U.S. Patent US5580977, issued May, 1990."@en . . . . . . . . . . "25%"@en . . . . "76470-66-1"@en . . . . "Streptococcus pyogenes"@en . " "@en . "Used to treat upper respiratory tract bacterial infections, chronic bronchitis, pneumonia, sinusitis, pharyntitis and tonsillitis, skin absceses, urinary tract infections and pyelonephritis caused by E. coli, S. pyogenes, S. aureus, S. saprphyticus, S. penumoniae, H. influenzae and M. catarrhalis."@en . . . "Escherichia coli"@en . . . . "withdrawn"@en . . . "Adverse effects include diarrhea, nausea, stomach upset, vomiting, headache, dizziness, rash, bone marrow depression."@en . . "# Dantzig AH, Duckworth DC, Tabas LB: Transport mechanisms responsible for the absorption of loracarbef, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells. Biochim Biophys Acta. 1994 Apr 20;1191(1):7-13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8155686 # Brogden RN, McTavish D: Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1993 May;45(5):716-36. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7686466 # Force RW, Nahata MC: Loracarbef: a new orally administered carbacephem antibiotic. Ann Pharmacother. 1993 Mar;27(3):321-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8453172 # Copper RD: The carbacephems: a new beta-lactam antibiotic class. Am J Med. 1992 Jun 22;92(6A):2S-6S. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1621741 "@en . . . "Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid."@en . . . "Take on an empty stomach. Food reduces Cmax by 50 to 60%."@en . . "Streptococcus pneumoniae"@en . . "Loracarbefum"@en . . . "Loracarbef"@en . . .